Company intelligence / Profile preview

Hy BioPharma

Jamison, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Hy BioPharma's lead asset HBP-347 (an HSP90 modulator) was discontinued after reaching a highest phase for glioblastoma and cutaneous T-cell lymphoma. HBP-412 (indication: multiple sclerosis) is in a pending approval/registration status; no substantive active clinical results available as of latest report.

Therapeutic areas: OncologyNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Hy BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hy BioPharma.

Explore the full profile